Zealand Pharma reports positive data from phase Ib trial

The candidate dapiglutide has been assessed both safe and well tolerated in humans and has several potential indications within gastrointestinal and metabolic diseases, reports Zealand Pharma.

Photo: Zealand Pharma / PR

Zealand Pharma has completed a small phase Ib study with the GLP1-GLP2 dual receptor agonist dapiglutide, it reports in a press release.

On Monday, the pharmaceutical company thus presented positive results from the study that lasted four weeks, during which dapiglutide was assessed to be safe and well tolerated in humans.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs